跳到正文
Brand AI

Illumina

争议事件

以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。

返回词条共 6 条

  1. 2022

    Illumina起诉Guardant Health涉嫌商业秘密问题

    提起诉讼

    Illumina起诉Guardant Health，指称Guardant联合创始人带走Illumina的机密文件，且Guardant癌症检测相关专利依赖这些信息。Guardant否认指控并称其毫无根据。

    来源摘录

    • Guardant has a sharply different version of events, arguing that Illumina’s claims have no merit
    • San Diego-based Illumina filed a lawsuit Wednesday in the U.S. District Court for the District of Delaware in which it says that Guardant’s co-founders, who are former Illumina employees, siphoned off tens of thousands of Illumina documents while creating their company.
    • The San Diego company wants the patents that Guardant filed turned over to them.
    来源

  2. 2021

    FTC起诉阻止因美纳收购Grail

    提起诉讼

    美国联邦贸易委员会对因美纳收购Grail提起诉讼，寻求阻止该交易。FTC称这项收购可能阻碍多癌种检测领域的创新；这是监管机构提出的担忧，并非法院裁定。

    来源摘录

    • FTC认为，这项收购交易可能会阻碍基因检测领域多种癌症检测技术的创新。
    • 美国联邦贸易委员会（FTC）周二表示，将寻求阻止该交易的达成。
    • FTC已经对这项收购提起诉讼
    来源

  3. 2020

    GRAIL 收购引发的监管争议

    Illumina 拟重新收购 GRAIL 引发了美国和欧洲的监管审查。监管机构担心 Illumina 可能限制或不利于依赖其测序技术的竞争性癌症检测开发商。Illumina 后来于 2024 年完成对 GRAIL 的剥离。

    来源

  4. 2020

    华大智造质疑基因测序仪招标公平性

    问题披露

    投标失利的华大智造公开质疑招标程序，称短时间完成流程且招标文件为Illumina设备量身定做、具有排他性。报道还称采购资金疑似来自特斯拉捐赠，并指出中标设备为Illumina产品；关于捐赠目的的说法属于质疑。

    来源摘录

    • 参与投标但失利的深圳企业华大智造在其官网公开发文，质疑此次招标程序不正义：在短时间内完成所有招投标流程，是为美国企业illumina的设备量身定做的招标文件，具有明确的排他性。
    • 值得注意的是，采购单位用于此次招标的500万元货款资金，疑似来自特斯拉此前的定向捐赠，而中标设备则是与其存在股东关联的美国企业illumina的产品。这也引发关于捐赠真实目的是利用中国政府机构宣传采购设备的质疑。
    来源

  5. 2020

    Illumina在英国和瑞典提起专利诉讼

    提起诉讼

    Illumina宣布，就涉及BGI测序产品的专利侵权问题提起两起诉讼：一起在英国针对MGI Tech Co., Ltd.和Latvia MGI Tech SIA，另一起在瑞典针对Latvia MGI Tech SIA。诉状指称相关方侵犯了Illumina的专利。

    来源摘录

    • The first complaint was filed against MGI Tech Co., Ltd. and Latvia MGI Tech SIA in the High Court of Justice, Chancery Division, Patents Court in the United Kingdom alleging infringement of four patents: EP 1 530 578 B1, EP 1 828 412 B2, EP 2 021 415 B1, and EP 3 002 289 B1. The second complaint was filed against Latvia MGI Tech SIA in the Patent and Market Court in Sweden alleging infringement of EP 3 002 289 B1.
    • The patents cover Illumina's proprietary sequencing-by-synthesis chemistry.
    • Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed two additional patent infringement suits relating to BGI's sequencing products, including the DNBSeq-400 (also known as MGISeq-2000), DNBSeq-T7, and related chemistry reagents.
    来源

  6. 2019

    Complete Genomics 对 Illumina 提起专利侵权反诉

    提起诉讼

    MGI 的美国关联公司 Complete Genomics 对 Illumina 提起专利侵权反诉。该反诉指称，Illumina 及其客户使用的基因测序仪和相关试剂侵犯了 Complete Genomics 涉及 Patterned Array 技术的专利。Complete Genomics 要求赔偿并申请禁令。

    来源摘录

    • Complete Genomics seeks damages and an injunction, which would require Illumina to stop selling the infringing products and provide infringement compensation.
    • Complete Genomics, a U.S. affiliate of MGI, has filed a patent infringement counterclaim against Illumina in U.S. District Court for the Northern District of California.
    • The lawsuit, filed September 30, alleges that Illumina and its customers are using various gene sequencers and related reagents, including NovaSeq 6000, HiSeq X Ten, HiSeq 3000, and HiSeq 4000, that infringe Complete Genomics' U.S. Patent No. 9,944,984 ("984 patent").
    来源